Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback